ASH · Insider Trading
Ashland Inc.
Every open-market purchase and sale reported by ASH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Sanat Chattopadhyay | Director | A | +212 deriv. | — |
| 2026-10-01 | Steven D Bishop | Director | A | +368 deriv. | — |
| 2026-09-23 | Osama M Musa | SVP and CTO | MIXED | +6,771 | +$467.61K |
| 2026-09-16 | Osama M Musa | SVP and CTO | A | +14,230 deriv. | — |
| 2026-08-12 | Robin E. Lampkin | SVP, GC & Secretary | MIXED | +1,280 | +$95.46K |
| 2026-08-05 | Peter T Thomas | Director | A | +978 deriv. | — |
| 2026-08-05 | Allen A Spizzo | Director | A | +978 deriv. | — |
| 2026-07-30 | Osama M Musa | SVP and CTO | M | +1,267 | +$73.44K |
| 2026-07-29 | Alessandra Faccin Assis | SVP and GM, Life Sciences | MIXED | +2,331 | +$154.73K |
| 2026-07-01 | Sanat Chattopadhyay | Director | A | +218 deriv. | — |
| 2026-07-01 | Steven D Bishop | Director | A | +379 deriv. | — |
| 2026-05-18 | Bertrand Loy | Director | A | +1,741 deriv. | — |
| 2026-05-11 | James P. Minicucci | SVP and GM, Personal Care | MIXED | +2,964 | +$163.05K |
| 2026-04-01 | Steven D Bishop | Director | A | +450 deriv. | — |
| 2026-04-01 | Sanat Chattopadhyay | Director | A | +258 deriv. | — |
| 2026-02-10 | Guillermo Novo | Chair of the Board and CEO | A | +32,096 deriv. | — |
| 2026-01-22 | Ashish K Kulkarni | Director | M | +2,113 | — |
| 2026-01-22 | Suzan F. Harrison | Director | A | +2,449 deriv. | — |
| 2026-01-21 | Scott Tozier | Director | A | +2,449 deriv. | — |
| 2026-01-21 | Jerome A Peribere | Director | A | +2,449 deriv. | — |
| 2026-01-21 | Sue Main | Director | A | +2,449 deriv. | — |
| 2026-01-21 | Sanat Chattopadhyay | Director | A | +2,449 deriv. | — |
| 2026-01-21 | Steven D Bishop | Director | A | +2,449 deriv. | — |
| 2026-01-05 | Sanat Chattopadhyay | Director | A | +245 deriv. | — |
| 2026-01-05 | Steven D Bishop | Director | A | +426 deriv. | — |
| 2025-11-21 | Samuel Richardson | VP, Controller and PAO | A | +5,650 deriv. | — |
| 2025-11-21 | Eileen Drury | SVP and Chief HRO | A | +12,851 deriv. | — |
| 2025-11-21 | Dago Caceres | SVP & GM, Specialty Additives | A | +13,814 deriv. | — |
| 2025-11-21 | James P. Minicucci | SVP and GM, Personal Care | A | +16,410 deriv. | — |
| 2025-11-21 | Osama M Musa | SVP and CTO | A | +20,733 deriv. | — |
| 2025-11-21 | William Whitaker | SVP, CFO & PFO | A | +33,411 deriv. | — |
| 2025-11-21 | Guillermo Novo | Chair of the Board and CEO | A | +141,359 deriv. | — |
| 2025-11-21 | Robin E. Lampkin | SVP, Gen Counsel and Secrty. | A | +12,887 deriv. | — |
| 2025-11-21 | Alessandra Faccin Assis | SVP and GM, Life Sciences | A | +19,943 deriv. | — |
| 2025-11-19 | Robin E. Lampkin | SVP, Gen Counsel and Secrty. | MIXED | +167 | +$8.28K |
| 2025-11-19 | William Whitaker | SVP, CFO & PFO | MIXED | +74 | +$3.67K |
| 2025-11-19 | Samuel Richardson | VP, Controller and PAO | MIXED | +75 | +$3.72K |
| 2025-11-19 | Osama M Musa | SVP and CTO | MIXED | +2,290 | +$119.41K |
| 2025-11-19 | Osama M Musa | SVP and CTO | MIXED | +641 | +$31.79K |
| 2025-11-19 | Eileen Drury | SVP and Chief HRO | MIXED | +287 | +$14.24K |
| 2025-11-19 | Guillermo Novo | Chair of the Board and CEO | MIXED | +3,559 | +$176.53K |
| 2025-11-17 | Samuel Richardson | VP, Controller and PAO | MIXED | +261 | +$13.61K |
| 2025-11-17 | William Whitaker | SVP, CFO & PFO | MIXED | +407 | +$21.22K |
| 2025-11-17 | Dago Caceres | SVP & GM, Specialty Additives | MIXED | +531 | +$28.20K |
| 2025-11-17 | Alessandra Faccin Assis | SVP and GM, Life Sciences | MIXED | +770 | +$40.89K |
| 2025-11-17 | James P. Minicucci | SVP and GM, Personal Care | MIXED | +1,543 | +$80.59K |
| 2025-11-17 | Eileen Drury | SVP and Chief HRO | MIXED | +1,157 | +$60.33K |
| 2025-11-17 | Guillermo Novo | Chair of the Board and CEO | MIXED | +10,552 | +$551.88K |
| 2025-11-17 | Robin E. Lampkin | SVP, Gen Counsel and Secrty. | MIXED | +1,502 | +$78.33K |
| 2025-10-02 | Sanat Chattopadhyay | Director | A | +300 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| J Kevin Willis | SVP and CFO | 270,566 | $19.57M |
| Guillermo Novo | Chair of the Board and CEO | 172,143 | $12.45M |
| Osama M Musa | SVP and CTO | 37,577 | $2.72M |
| Eric N Boni | VP, Finance & Prinpl Acctg Off | 22,319 | $1.61M |
| Alessandra Faccin Assis | SVP and GM, Life Sciences | 8,215 | $594.11K |
| Robin E. Lampkin | SVP, GC & Secretary | 7,690 | $556.14K |
| Eileen Drury | SVP and Chief HRO | 7,601 | $549.70K |
| James P. Minicucci | SVP and GM, Personal Care | 7,221 | $522.22K |
| Karl R. Bostaph | Senior VP Operations | 7,165 | $518.17K |
| Ashish K Kulkarni | Director | 2,113 | $152.81K |
| William Whitaker | SVP, CFO & PFO | 2,049 | $148.18K |
| Suzan F. Harrison | Director | 1,931 | $139.65K |
| Sue Main | Director | 1,883 | $136.18K |
| Jerome A Peribere | Director | 1,883 | $136.18K |
| Janice Teal | Director | 1,883 | $136.18K |
| Samuel Richardson | VP, Controller and PAO | 1,104 | $79.84K |
| Dago Caceres | SVP & GM, Specialty Additives | 531 | $38.40K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.